Clinical Trial Update: A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months [Phase 1]

View source ↗

Summary

A completed Phase 1 trial evaluating safety and immunogenicity of 200 mcg gp120 (CHO) BIOCINE formulated with MF59 compared with MF59 emulsion alone, given as t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MF59 emulsion (MF59 adjuvant)
• gp120 (CHO) BIOCINE in MF59 emulsion (gp120 vaccine in MF59-adjuvanted formulation)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED